A 32-year-old multigravida (G3P2) from Mumbai with BMI 29 kg/m² and a family history of type 2 diabetes is diagnosed with gestational diabetes at 26 weeks on 75 g OGTT (fasting 98 mg/dL, 2-hour 160 mg/dL). She is counseled on medical nutrition therapy and starts home glucose monitoring. After 3 weeks of strict dietary adherence, her fasting glucose is consistently 105–110 mg/dL and 2-hour postprandial glucose is 140–150 mg/dL. What is the most appropriate pharmacological agent to initiate?

Explanation

## Pharmacotherapy for Gestational Diabetes: First-Line Agent Selection ### Clinical Context: Failed Dietary Control **Key Point:** The patient has failed medical nutrition therapy (fasting glucose 105–110 mg/dL and 2-hour postprandial 140–150 mg/dL both exceed targets of <95 mg/dL and <120 mg/dL, respectively). Pharmacotherapy is now indicated. ### Comparison of First-Line Agents in GDM | Agent | Mechanism | Safety in Pregnancy | Evidence | Guideline Status | |---|---|---|---|---| | **Insulin** | Exogenous glucose control | Gold standard; no teratogenicity | Extensive RCT data (ACHOIS, HAPO) | **First-line by ACOG, FIGO, ICMR** | | **Metformin** | Reduces hepatic glucose production | Generally safe; crosses placenta | Growing evidence; non-inferiority to insulin in some trials | Alternative first-line (ACOG 2018) | | **Glyburide** | Stimulates pancreatic β-cell insulin secretion | Minimal placental transfer | Older trials show efficacy | **NOT recommended in India; second-line in USA** | | **Acarbose** | Delays carbohydrate absorption | Safe; minimal systemic absorption | Limited GDM-specific data | Rarely used; not first-line | ### Why Insulin is the Gold Standard in GDM ```mermaid flowchart TD A[Failed MNT in GDM]:::outcome --> B[Choose Pharmacotherapy]:::decision B --> C[Insulin]:::action B --> D[Metformin]:::action C --> E[No placental transfer<br/>No teratogenicity<br/>Extensive safety data]:::outcome D --> F[Crosses placenta<br/>Long-term fetal effects unknown<br/>Growing but limited evidence]:::outcome E --> G[Preferred in India<br/>ACOG/FIGO consensus]:::action F --> H[Acceptable alternative<br/>if patient refuses insulin]:::action ``` **High-Yield:** Insulin is the **first-line pharmacological agent** for GDM in India, USA, and most developed nations. It does NOT cross the placenta (molecular weight >5000 Da) and has the longest safety record in pregnancy. **Clinical Pearl:** Metformin is an acceptable alternative in resource-limited settings or when patient refuses insulin, but it crosses the placenta and long-term fetal metabolic effects are still being studied. ACOG 2018 now lists it as co-first-line, but ICMR and FIGO still prefer insulin as the primary choice. **Mnemonic:** **INSULIN FIRST** in GDM - **I**ntact placental barrier (does not cross) - **N**o teratogenic risk - **S**afety data extensive (decades of use) - **U**niversal guideline recommendation - **L**ong-acting and rapid-acting formulations available - **I**mmediately effective - **N**o systemic maternal side effects - **S**tandard of care worldwide - **U**nder-utilized in resource-limited settings - **L**ife-saving for mother and fetus ### Why NOT Glyburide? **Warning:** Glyburide (glibenclamide) is a **second-generation sulfonylurea** that: - Stimulates fetal pancreatic β-cells, risking neonatal hypoglycemia - Has higher placental transfer than older data suggested (recent studies show ~10% transfer) - Is associated with increased neonatal hypoglycemia and respiratory distress in some trials - Is **NOT recommended as first-line in India** (ICMR guidelines 2018) - May be used as second-line if insulin unavailable or unaffordable ### Insulin Dosing in GDM - **Starting dose:** 0.2 U/kg/day (divided into NPH + rapid-acting) - **Titration:** Increase by 2–4 U every 3–5 days based on home glucose monitoring - **Typical range:** 10–30 U/day by third trimester - **Formulations:** Human NPH (intermediate-acting) + rapid-acting (lispro, aspart) preferred [cite:ICMR GDM Guidelines 2018, ACOG Practice Bulletin 190, FIGO GDM Consensus 2015]